Search | Clinical Trials Finder

Conditions: Yellow Fever
Interventions: Yellow Fever 17DD Vaccine; Biological
Lead sponsor: Centers for Disease Control and Prevention; Federal
Eligibility: 9 Months to 23 Months
Enrollment: 1,788 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2021
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: HIV Infections
Interventions: EP HIV-1090; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 40 Years
Enrollment: 42 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Ends 2005
U.S. locations: 4
States / cities: Boston, Massachusetts • St Louis, Missouri • Providence, Rhode Island

Conditions: Cancer, Influenza Viral Infections
Interventions: Standard Trivalent Influenza Vaccine, High-Dose Influenza Vaccine; Biological
Lead sponsor: Saad Jamshed MD; Other
Eligibility: 18 Years to 64 Years
Enrollment: 105 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 2
States / cities: Rochester, New York

Conditions: Hepatitis C Infection
Interventions: Recombivax; Drug
Lead sponsor: Rockefeller University; Other
Eligibility: 18 Years to 62 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: New York, New York

Conditions: Dengue
Interventions: rDEN4delta30-4995, Placebo; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 50 Years
Enrollment: 84 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2007
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Prostate Cancer
Interventions: aldesleukin, recombinant fowlpox-prostate specific antigen vaccine, recombinant vaccinia prostate-specific antigen vaccine, recombinant vaccinia-B7.1 vaccine, sargramostim, nilutamide; Biological · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older · Male only
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2000
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: HIV Infections
Interventions: HIVAX, saline solution; Biological
Lead sponsor: GeneCure Biotechnologies; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2020
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Human Papilloma Virus (HPV) Vaccine
Interventions: HPV MISTICS -Provider Level, HPV MISTICS - Parent Level, HPV MISTICS- HPV Vaccine Champion Level; Behavioral
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 564 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Marburg Virus Disease
Interventions: rVSV∆G-MARV-GP, Placebo; Biological · Other
Lead sponsor: International AIDS Vaccine Initiative; Network
Eligibility: 18 Years to 50 Years
Enrollment: 112 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2028
U.S. locations: 2
States / cities: Washington D.C., District of Columbia • Lenexa, Kansas

Conditions: Infections, Papillomavirus
Interventions: Gynaecological follow-up; Other
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 2,022 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2014
U.S. locations: 18
States / cities: Clearwater, Florida • Miami, Florida • Honolulu, Hawaii + 14 more

Conditions: COVID-19
Interventions: Remote study participation and self-collection of specimens, Traditional clinical trial participation with clinician-collected specimens; Other
Lead sponsor: Biomedical Advanced Research and Development Authority; Federal
Eligibility: 18 Years and older
Enrollment: 4,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2026
U.S. locations: 16
States / cities: Vestavia Hills, Alabama • Mesa, Arizona • Fair Oaks, California + 12 more

Conditions: Healthy Adult Immune Responses to Vaccine
Interventions: VRC-EBOADC069-00-VP, VRC-EBOADC076-00-VP; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 65 Years
Enrollment: 143 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2017
U.S. locations: 3
States / cities: Decatur, Georgia • Baltimore, Maryland • Bethesda, Maryland

Conditions: HIV Infections
Interventions: ALVAC-HIV MN120TMG (vCP205), ALVAC-RG Rabies Glycoprotein (vCP65), rgp120/HIV-1 SF-2; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 60 Years
Enrollment: 76 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Ends 1997
U.S. locations: 6
States / cities: Birmingham, Alabama • Baltimore, Maryland • St Louis, Missouri + 3 more

Conditions: Human Papillomavirus Viruses, Papillomavirus Vaccines
Interventions: K-Talk Intervention (Storytelling and K-Bot), Storytelling Intervention, K-Bot Intervention, Written Information; Other
Lead sponsor: University of Cincinnati; Other
Eligibility: 18 Years to 45 Years
Enrollment: 120 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Respiratory Syncytial Viruses, Respiratory Tract Infections
Interventions: Ad26.RSV.preF (1*10^11 vp), Ad26.RSV.preF (5*10^10 vp), Placebo; Biological · Drug
Lead sponsor: Janssen Vaccines & Prevention B.V.; Industry
Eligibility: 12 Months to 50 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: Newton, Kansas

Conditions: SARS-CoV-2, COVID-19 Vaccines
Interventions: Vaccination; Biological
Lead sponsor: Pfizer; Industry
Eligibility: Not listed
Enrollment: 19,853,610 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: New York, New York

Conditions: Ebola Hemorrhagic Fever, Ebola Virus Disease, Ebola Virus Vaccines, Envelope Glycoprotein, Ebola Virus, Filovirus
Interventions: VRC-EBOADV018-00-VP; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 50 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2009
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: HIV Infections
Interventions: Therapeutic vaccinations from A5058s; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 78 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 2004
U.S. locations: 14
States / cities: Torrance, California • Aurora, Colorado • Indianapolis, Indiana + 5 more

Conditions: HIV Infections
Interventions: AVX101, placebo; Biological · Other
Lead sponsor: AlphaVax, Inc.; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2003 – 2005
U.S. locations: 5
States / cities: Baltimore, Maryland • New York, New York • Rochester, New York + 2 more

Conditions: HIV Infections
Interventions: SAAVI DNA-C2 vaccine, SAAVI MVA-C vaccine, Placebo; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 45 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2013
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: Pancreatic Ductal Adenocarcinoma, Colorectal Cancer, KRAS G12D, KRAS G12R, KRAS G12V, KRAS G12A, KRAS G12C, KRAS G12S, KRAS G13D, NRAS G12D, NRAS G12R, NRAS G12V, NRAS G12C, NRAS G12S
Interventions: ELI-002 7P; Drug
Lead sponsor: Elicio Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 158 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 28
States / cities: Gilbert, Arizona • Phoenix, Arizona • Duarte, California + 21 more

Conditions: Covid19
Interventions: Opt-In (Call-Back), Opt-in (In-Bound), Standard Message, Clinician Endorsement, Scarcity, Opt-Out Framing, Phone Call; Behavioral
Lead sponsor: University of Pennsylvania; Other
Eligibility: 16 Years and older
Enrollment: 19,554 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Infections, Papillomavirus
Interventions: Cervarix™, Havrix™-based investigational formulation; Biological
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 15 Years to 25 Years · Female only
Enrollment: 18,729 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004 – 2009
U.S. locations: 50
States / cities: Birmingham, Alabama • Fountain Valley, California • San Diego, California + 39 more

Conditions: Hepatitis B
Interventions: Hepatitis B Vaccine (Recombinant); Biological
Lead sponsor: Rockefeller University; Other
Eligibility: 18 Years to 60 Years
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: New York, New York

Search by objective public record fields.

Immunogenicity of Fractional One-fifth and One-half Doses of Yellow Fever Vaccine Compared to Full Dose in Children 9-23 Months Old

Safety of and Immune System Response to an HIV Vaccine (EP HIV-1090) in HIV Uninfected Adults

Study Comparing High-Dose Flu Vaccine to Standard Vaccine in Cancer Patients Less Than 65 Receiving Chemotherapy

Effects of Persistent Innate Immune Activation on Vaccine Efficacy

Safety of and Immune Response to a Dengue Virus Vaccine (rDEN4delta30-4995) in Healthy Adults

Vaccine Therapy Plus Sargramostim and Interleukin-2 Compared With Nilutamide Alone in Treating Patients With Prostate Cancer

Safety and Immunogenicity of HIVAX in HIV-1 Infected Subjects

HPV Multilevel Intervention Strategies Targeting Immunization in Community Settings (HPV MISTICS)

A Phase 1 Randomized, Observer-blind, Placebo-controlled, Dose-escalation Clinical Trial to Evaluate the Safety and Immunogenicity of rVSV∆G-MARV-GP Vaccine in Adults in Good General Health

Gynaecological Follow-up of a Subset of 580299/008 (NCT00122681) Study Subjects

Project REMOTE (REimagining Measurements and Operations of Translational Endpoints)

Safety, Tolerability, and Immunogenicity of the Ebola Chimpanzee Adenovirus Vector Vaccine (cAd3-EBO), VRC-EBOADC069-00-VP, in Healthy Adults

A Phase I Safety and Immunogenicity Trial of Live Recombinant Canarypox ALVAC-HIV (vCP205) in HIV-1 Uninfected Adult Volunteers

Let's K-Talk - HPV Study for Ethnic Koreans

A Study to Evaluate the Safety, Tolerability and Immunogenicity of an Investigational RSV Vaccine Candidate (Ad26.RSV.preF) in Adults 18 to 50 Years of Age, and RSV-seropositive Toddlers 12 to 24 Months of Age

Effectiveness of BNT162b2 Formulations Using State Vaccine Registry and Insurance Claims Data

Experimental Vaccine for Prevention of Ebola Virus Infection

Effects of Therapeutic HIV Vaccination on Control of HIV After Discontinuation of Anti-HIV Drugs

Safety of an HIV Vaccine (AVX101) in HIV Uninfected Volunteers in the United States and South Africa

Safety of and Immune Response to Two HIV Vaccines: SAAVI DNA-C2 Boosted With SAAVIMVA-C, in HIV-Negative Adults

A Study of ELI-002 7P in Subjects With KRAS/NRAS Mutated Solid Tumors

COVID-19 Vaccine Text Outreach

Human Papilloma Virus (HPV) Vaccine Efficacy Trial Against Cervical Pre-cancer in Young Adults With GlaxoSmithKline (GSK) Biologicals HPV-16/18

Pilot Study: Gene Expression Profiling of Immune Response to HBV Vaccination in Healthy Volunteers